Ocular Therapeutix Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. It specializes in ophthalmology, particularly advancing treatments for retinal disorders such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR). The company's pipeline features AXPAXLI (OTX-TKI), a tyrosine kinase inhibitor delivered via intravitreal bioresorbable implant designed for extended durability, currently in late-stage Phase 3 clinical programs including the SOL-1 superiority trial and HELIOS registrational program. Ocular Therapeutix Inc. also markets DEXTENZA, a commercial intracanalicular insert for ocular pain and inflammation post-surgery. Additional candidates like OTX-TP target glaucoma and dry eye disease. Headquartered in Bedford, Massachusetts and founded in 2006, the company plays a key role in the retinal therapeutics market by leveraging bioresorbable hydrogel technology to improve patient outcomes and reduce treatment burden through sustained drug delivery systems.